• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer

    4/12/21 8:00:00 AM ET
    $JNCE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNCE alert in real time by email

    CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Dmitri Wiederschain, Ph.D., as Chief Scientific Officer.

    "The addition of Dmitri to the Jounce team comes at an exciting juncture in our company development," said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. "Dmitri brings a broad knowledge of contemporary immuno-oncology approaches, tumor immunology and cancer biology. His expertise with preclinical target discovery and first-in-human research will provide us with invaluable contributions in our work towards delivering the right immunotherapies to the right patients."

    "Jounce's scientific approach to interrogating the tumor microenvironment is what drew me to the company. With a career deeply rooted in cancer biology and immuno-oncology drug discovery, I believe that Jounce is strongly positioned to make a meaningful impact on today's therapeutic landscape," said Dmitri Wiederschain, Ph.D., chief scientific officer of Jounce Therapeutics. "With an exciting discovery pipeline and engine, I am looking forward to collaborating closely with the team to continue to advance not only our two proof of concept studies, but also new discovery programs."

    Dr. Wiederschain brings more than 15 years of pharmaceutical industry experience as a scientific leader and drug developer. Dr. Wiederschain joins Jounce from Sanofi, where he held roles of increasing responsibility over the course of 11 years and helped build a pipeline encompassing a diverse array of immuno-oncology approaches. Most recently, he was vice president and global head of immuno-oncology research where he oversaw projects from conception to IND stage, built productive partnerships and research collaborations and advanced 10 development candidates into the clinic while leading a large international team of scientists in both the U.S. and France. Prior to joining Sanofi, Dr. Wiederschain was an investigator and laboratory head of discovery biology, and prior to that a presidential post-doctoral fellow in oncology at Novartis Institutes for Biomedical Research. He has also co-authored 45 publications in peer-reviewed journals to date. Dr. Wiederschain holds a Ph.D. in Biological Sciences and an A.L.B. in Natural Sciences from Harvard University.

    In connection with Dr. Wiederschain's appointment, the compensation committee of Jounce's Board of Directors has approved the grant of a non-qualified stock option award to purchase an aggregate of 225,000 shares of Jounce's common stock to him. The grant date of the stock option will be May 1, 2021, and the stock option will have an exercise price equal to the closing price of Jounce's common stock on May 1, 2021. The stock option was granted outside of Jounce's 2017 Stock Option and Incentive Plan as an inducement material to Dr. Wiederschain's acceptance of employment with Jounce in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has a 10-year term and vests over four years, with 25% of the award vesting on the first anniversary of his employment, and as to an additional 1/12th of the shares quarterly thereafter, subject to Dr. Wiederschain's continued employment through applicable vesting dates (subject to the terms and conditions of the stock option agreement covering the grant).

    About Jounce Therapeutics

    Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.

    Investor and Media Contacts:

    Malin Deon

    Jounce Therapeutics, Inc.

    +1-857-259-3843

    [email protected] 

    Mark Yore

    Jounce Therapeutics, Inc.

    +1-857-200-1255

    [email protected] 



    Primary Logo

    Get the next $JNCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNCE

    DatePrice TargetRatingAnalyst
    5/11/2022$15.00 → $7.00Outperform → Neutral
    Robert W. Baird
    5/6/2022$15.00 → $20.00Outperform → Strong Buy
    Raymond James
    3/16/2022$17.00Outperform
    SMBC Nikko
    2/4/2022Market Perform → Outperform
    Cowen & Co.
    11/5/2021$10.00 → $15.00Outperform
    Raymond James
    9/14/2021$10.00Market Perform → Outperform
    Raymond James
    More analyst ratings

    $JNCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Jounce Therapeutics Announces Closing of Tender Offer

      CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Concentra Biosciences, LLC ("Concentra"), through its wholly owned subsidiary Concentra Merger Sub, Inc. ("Concentra Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of the common stock of Jounce for $1.85 per share in cash plus a non-tradeable contingent value right (a "CVR") per share. The $1.85 per share upfront consideration represents a premium of approximately

      5/3/23 8:35:17 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. ("Jounce" or the "Company") and Redx Pharma plc ("Redx") have agreed to terminate their proposed business combination following the decision by Jounce's Board of Directors to withdraw the recommendation for the all-share merger transaction with Redx (the "Redx Business Combination"). Jounce's decision was based upon the receipt of an unsolicited proposal from Concentra Biosciences, LLC ("Conc

      4/3/23 2:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights

      NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE) ("Jounce" or the "Company"), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right (the "CVR"). The $1.85 per share upfront con

      3/27/23 9:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jounce Therapeutics downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Jounce Therapeutics from Outperform to Neutral and set a new price target of $7.00 from $15.00 previously

      5/11/22 6:18:27 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics upgraded by Raymond James with a new price target

      Raymond James upgraded Jounce Therapeutics from Outperform to Strong Buy and set a new price target of $20.00 from $15.00 previously

      5/6/22 7:22:10 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SMBC Nikko initiated coverage on Jounce Therapeutics with a new price target

      SMBC Nikko initiated coverage of Jounce Therapeutics with a rating of Outperform and set a new price target of $17.00

      3/16/22 7:50:25 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Leadership Updates

    Live Leadership Updates

    See more
    • Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors

      CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors. "It's incredibly exciting to welcome Jigar to our board of directors. Not only does Jigar bring over 20 years of biotechnology industry experience, but he also comes with a unique position as an early employee of the company at its inception," said Richard Murray, Ph.D., chief executive offic

      9/15/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Dmitri Wiederschain, Ph.D., as Chief Scientific Officer. "The addition of Dmitri to the Jounce team comes at an exciting juncture in our company development," said Richard Murray, Ph.D., chief executive officer and president of Jounce Therapeutics. "Dmitri brings a broad knowledge of contemporary immuno-oncology approaches, tumor immunology and cancer biology. His expertise with preclinical target discovery and first-in-human research will

      4/12/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors

      CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of Luisa Salter-Cid, Ph.D., to its board of directors. “We are thrilled to welcome Luisa to our board of directors,” said Perry Karsen, chairman of the board of Jounce Therapeutics. “Luisa brings over 20 years of experience in the healthcare industry, specifically in immunology and immuno-oncology, and we look forward to the unique and valuable perspective that her strategic leadership will bring to Jounce.” Dr. Salter-Cid currently serves a

      2/12/21 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Concentra Biosciences, Llc

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:38:21 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Tang Kevin C

      4 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:37:26 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Concentra Biosciences, Llc claimed ownership of 36,367,727 shares

      3 - Jounce Therapeutics, Inc. (0001640455) (Issuer)

      5/5/23 4:35:30 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/14/24 8:50:07 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Jounce Therapeutics Inc.

      SC 13G - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/9/24 4:05:34 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Jounce Therapeutics Inc. (Amendment)

      SC 13G/A - Jounce Therapeutics, Inc. (0001640455) (Subject)

      2/2/24 12:28:25 PM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Jounce Therapeutics Inc.

      15-12G - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/15/23 7:40:24 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Jounce Therapeutics Inc.

      EFFECT - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/5/23 12:15:08 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Jounce Therapeutics Inc.

      EFFECT - Jounce Therapeutics, Inc. (0001640455) (Filer)

      5/5/23 12:15:07 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNCE
    Financials

    Live finance-specific insights

    See more
    • Redx and Jounce Announce Recommended Business Combination

      Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to include discovery projects from both Redx and Jounce Combined group to be called Redx Inc. listed on Nasdaq under the ticker REDX and led by Redx CEO Lisa Anson with cash runway into H2 2025 ALDERLEY PARK, United Kingdom and CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Redx Pharma (AIM: REDX) and Jounce Therapeutics, Inc. (NASDAQ:JNCE) today announce an unanimously recommended Business Combination of the

      2/23/23 2:30:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics Reports Third Quarter 2022 Financial Results

      - INNATE trial of JTX-8064 +/- pimivalimab Phase 1 Dose Escalation data at ESMO-IO Annual Congress - - SELECT randomized trial of pimivalimab +/- vopratelimab phase 2 data at ESMO-IO Annual Congress - - Two preclinical posters on JTX-1484 and LILRB family at SITC 2022 - - Ended the quarter with $130.3 million in cash, cash equivalents and investments - - Company to host conference call and webcast today at 8:00 AM ET - CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported financial results for the third quart

      11/10/22 7:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022

      CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022. Jounce Therapeutics' management team will host a webcast and live conference call at 8:00 a.m. ET. Conference Call and WebcastTo access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under "Events & Presentations" in the Investors and Me

      10/27/22 8:00:00 AM ET
      $JNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care